Industry News Sofinnova Partners BioPharma Dive
Sofinnova Closes €725M Crossover Fund to Bridge Europe's Late-Stage Financing Gap
- Sofinnova Partners closed Sofinnova Crossover II at €725M (about $815M), its largest fund; the firm manages about €4B.
- It plans around 15 investments in late-stage drug and device companies near commercialization, mostly European.
- Partner Kinam Hong frames Europe's problem as scale-up financing, not innovation; BioPharma Dive data show over 70 private rounds this year went to Phase 1-or-later biotechs.
The signal is crossover money returning as the IPO window reopens. A €725M fund written into roughly 15 names implies cheques large enough to carry companies to a listing or a sale, the layer European biotech has lacked. Watch whether it truly stays in Europe: US-listing pull and US-heavy co-investors often drag the best companies westward. Abivax's rise is the pitch; the test is repeating it.
Source: BioPharma Dive ↗ One of Europe's leading VCs banks a €725M 'crossover' fund